Russian Journal of ImmunologyRussian Journal of ImmunologyРоссийский иммунологический журнал1028-72212782-7291Russian Society of Immunology1727910.46235/1028-7221-17279-IAPORIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИResearch ArticleInflammation and psoriasis: immunopathological characteristics and therapeutic advancesВоспаление и псориаз: иммунопатологические характеристики и успехи терапииZahzeh Ait KaciMeriem RabiaЗахзи Аит КазиМерием Рабиа
Algeria

PhD in Biology of the Normal and Pathological Cell, Associate Professor, Department of Biology, Faculty of Natural and Life Sciences

д.б.н. (биология нормальных и патологических клеток), доцент, кафедра биологии, факультет естественных и биологических наук

rabia.zahzeh@univ-sba.dzRemlaNesrineРемлаНесрин
Algeria

PhD in Biology of the Normal and Pathological Cell, Associate Professor, Department of Biology, Faculty of Natural and Life Sciences, Laboratory of Molecular Microbiology, Proteomics and Health

д.б.н. (биология нормальных и патологических клеток), доцент, кафедра биологии, факультет естественных и биологических наук, лаборатория молекулярной микробиологии

rabia.zahzeh@univ-sba.dzOualiSihemeОуалиСихеме
Algeria

PhD in Biochemistry and Immunology, Assistant Professor, Department of Biology, Faculty of Natural and Life Sciences, Laboratory of Molecular Microbiology, Proteomics and Health

д.б.н. (биохимия и иммунология), ассистент, кафедра биологии, факультет естественных и биологических наук, лаборатория молекулярной микробиологи

rabia.zahzeh@univ-sba.dzZahzehTouriaЗахзиТурия
Algeria

PhD in Nutrition, Professor of Nutrition, Department of Biology, Faculty of Natural and Life Sciences, Laboratory of Molecular Microbiology, Proteomics and Health

д-р нутрициологии, профессор, кафедра биологии, факультет естественных и биологических наук, лаборатория молекулярной микробиологии

rabia.zahzeh@univ-sba.dzDjillali Liabes University of Sidi Bel AbbesУниверситет Джиллали Лиабеса в Сиди-Бель-Аббесе05082025220420262923633723005202525072025Copyright ©; 2026, Zahzeh Ait Kaci M.R., Remla N., Ouali S., Zahzeh T.Copyright ©; 2026, Захзи Аит Кази М.Р., Ремла Н., Оуали С., Захзи Т.2026Zahzeh Ait Kaci M.R., Remla N., Ouali S., Zahzeh T.Захзи Аит Кази М.Р., Ремла Н., Оуали С., Захзи Т.https://creativecommons.org/licenses/by/4.0https://rusimmun.ru/jour/article/view/17279

Psoriasis is a chronic systemic inflammatory disease primarily affecting the skin, characterized by excessive keratinocyte proliferation and T lymphocyte infiltration. This multifactorial condition results from complex interactions between genetic, environmental, and immune factors. This retrospective study analysed the demographic, clinical, and therapeutic profiles of 136 psoriasis patients admitted to the Internal Medicine and Dermatology departments of the University Hospital Centre of Sidi Bel Abbès (Western Algeria). The cohort showed a balanced sex distribution (50.7% male, 49.3% female) with a mean age of 51.28±14.19 years. The most prevalent forms were erythrodermic (45.8%), vulgaris (32.2%), and pustular (19.2%). The main treatments included corticosteroids (45.6%), topical creams and emollients (27.2%), and immunosuppressants (25%). Laboratory findings revealed elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), reflecting chronic systemic inflammation. Patients with high ESR levels also exhibited increased blood glucose, blood pressure, triglycerides, and total cholesterol. These findings reinforce the systemic nature of psoriasis and highlight the importance of investigating its molecular and immunological mechanisms. They also support the need for comprehensive and personalized management, especially in the context of associated comorbidities such as cardiovascular disease.

Psoriasis is a chronic systemic inflammatory disease primarily affecting the skin, characterized by excessive keratinocyte proliferation and T lymphocyte infiltration. This multifactorial condition results from complex interactions between genetic, environmental, and immune factors. This retrospective study analysed the demographic, clinical, and therapeutic profiles of 136 psoriasis patients admitted to the Internal Medicine and Dermatology departments of the University Hospital Centre of Sidi Bel Abbès (Western Algeria). The cohort showed a balanced sex distribution (50.7% male, 49.3% female) with a mean age of 51.28±14.19 years. The most prevalent forms were erythrodermic (45.8%), vulgaris (32.2%), and pustular (19.2%). The main treatments included corticosteroids (45.6%), topical creams and emollients (27.2%), and immunosuppressants (25%). Laboratory findings revealed elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), reflecting chronic systemic inflammation. Patients with high ESR levels also exhibited increased blood glucose, blood pressure, triglycerides, and total cholesterol. These findings reinforce the systemic nature of psoriasis and highlight the importance of investigating its molecular and immunological mechanisms. They also support the need for comprehensive and personalized management, especially in the context of associated comorbidities such as cardiovascular disease.

psoriasissystemic inflammationC-reactive proteinerythrocyte sedimentation ratemetabolic syndromeAlgeriaпсориазсистемное воспалениеС-реактивный белокскорость оседания эритроцитовметаболический синдромАлжирAlamri A., Alqahtani R., Alshareef I., Alshehri A., Balkhy A. Psoriasis in Saudi Population: Gender Differences in Clinical Characteristics and Quality of Life. Cureus, 2022, Vol. 14, no. 3, e22892. doi: 10.7759/cureus.22892.Amador J.R., Becerra-Arias C., Rojas-Zuleta W.G., Castro-Ayarza J.R., Franco M., Barbosa-Rengifo M. Clinical characteristic and outcomes of psoriasis patients in a multicentre outpatient healthcare institution in Colombia. Rev. Colomb. Reumatol., 2024, Vol. 31. doi: 10.1016/j.rcreu.2024.04.008.Armstrong A.W., Mehta M.D., Schupp C.W., Gondo G.C., Bell S.J., Griffiths C.E.M. Psoriasis prevalence in adults in the United States. JAMA Dermatol., 2021, Vol. 157, no. 8, pp. 940-946.Bartlett K.J., Vo A.P., Rueckert J., Wojewoda C., Steckel E.H., Stinnett-Donnelly J., Repp A.B. Promoting appropriate utilisation of laboratory tests for inflammation at an academic medical centre. BMJ Open Qual., 2020, Vol. 9, no. 1, e000788. doi: 10.1136/bmjoq-2019-000788Beygi S., Lajevardi V., Abedini R. C-reactive protein in psoriasis: a review of the literature. J. Eur. Acad. Dermatol. Venereol., 2014, Vol. 28, no. 6, pp. 700-711.Bronckers I.M.G.J., Paller A.S., van Geel M.J., van de Kerkhof P.C.M., Seyger M.M. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Pediatr. Drugs, 2015, Vol. 17, pp. 373-384.Cao L., Lu L., Yu Y., Zhou H., Lin B. Clinical characteristics of patients with a family history of psoriasis: an observational epidemiological study in Chinese Han population. Front. Med., 2024, Vol. 11, 1455953. doi: 10.3389/fmed.2024.1455953.Castro-Ayarza J.R., Barbosa-Rengifo M., Franco-Franco M., Amador J.R., Cárdenas-Rojas P., Becerra-Arias C., Donado-Gómez J., Duque-Zapata N. Biological therapy optimization in patients with psoriasis by reducing the dose or increasing the time interval, in a specialized centre in Colombia. Rev. Colomb. Reumatol., 2023, Vol. 30, Suppl. 1, pp. S65-S69.Chodorowska G., Wojnowska D., Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J. Eur. Acad. Dermatol. Venereol., 2004, Vol. 18, no. 2, pp. 180-183.Gao Y., Xu T., Wang Y., Hu Y., Yin S., Qin Z., Yu H. Pathophysiology and treatment of psoriasis: from clinical practice to basic research. Pharmaceutics, 2025, Vol. 17, no. 1, 56. doi: 10.3390/pharmaceutics17010056.Gökalp H. Effect of psoriasis severity on inflammation parameters: Controlled study. Turkderm-Turk. Arch. Dermatol. Venereol., 2018, Vol. 52, pp. 91-94.Griffiths C.E.M., Armstrong A.W., Gudjonsson J.E., Barker J.N.W.N. Psoriasis. Lancet, 2021, Vol. 397, no. 10281, pp. 1301-1315.Iskandar I.Y.K., Ashcroft D.M., Warren R.B., Lunt M., McElhone K., Smith C.H., Reynolds N.J., Griffiths C.E.M. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. Br. J. Dermatol., 2017, Vol. 177, no. 5, pp. 1410-1421.Jonak C., Göttfried I., Perl-Convalexius S., Gruber B., Schütz-Bergmayr M., Vujic I., Weger W., Schicher N., Semlin L., Hemetsberger M., Cordey M., Sator P. Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study. Ther. Adv. Chronic Dis., 2023, Vol. 14, 20406223231152785. doi: 10.1177/20406223231152785.Kashyap M., Gupta B., Das D. The diagnosis of early psoriatic arthritis in patients of psoriasis visiting dermatology outpatient department. IP Indian J. Clin. Exp.Dermatol., 2024, Vol. 10, no. 3, pp. 266-270.Kim W.B., Jerome D., Yeung J. Diagnosis and management of psoriasis. Can. Fam. Physician, 2017, Vol. 63, no. 4, pp. 278-285.Kim Y.H., Kim S.I., Park B., Lee E.S. Clinical characteristics of psoriasis for initiation of biologic therapy: a cluster analysis. Ann. Dermatol., 2023, Vol. 35, no. 2, pp. 132-139.Kimak-pielas A., Robak E., Zajdel R., Zebrowska A. Demographics, Disease Characteristics, and Treatment patterns of patients with plaque psoriasis Treated with Biological Drugs: The Experience of a Single-Centre Study in poland. J. Clin. Med., 2024, Vol. 13, 7647. doi: 10.3390/jcm13247647.Korman N.J. Management of psoriasis as a systemic disease: what is the evidence? Br. J. Dermatol., 2020, Vol. 182, no. 4, pp. 840-848.Kustán P., Kőszegi T., Miseta A., Péter I., Ajtay Z., Kiss I., Németh B. Urinary Orosomucoid: A potential Marker of Inflammation in psoriasis. Int. J. Med. Sci., 2018, Vol. 15, no. 11, pp. 1113-1117.Luan Y.Y., Yao Y.M. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Front. Immunol., 2018, Vol. 9, 1302. doi: 10.3389/fimmu.2018.01302.Majid A., Fouad M. Serum visfatin, resistin levels and inflammation markers in psoriasis. Ukr. Biochem. J., 2022, Vol. 94, no. 6, pp. 48-56.Malatestinic W., Nordstrom B., Wu J.J., Goldblum O., Solotkin K., Lin C.Y., Kistler K., Fraeman K., Johnston J., Hawley L.L., Sicignano N., Araujo A. Characteristics and medication use of psoriasis patients who may or may not qualify for randomized controlled trials. J. Manag. Care Spec. Pharm., 2017, Vol. 23, no. 3, pp. 370-381.Metin Z., Tur K., Durmaz K., Akogul S., Akca H.M., Imren I.G., Demir N.B.O., Ozkoca D. A comprehensive investigation of novel and traditional inflammatory and metabolic markers as predictive indicators in psoriasis. Int. J. Dermatol., 2023, Vol. 62, no. 10, pp. 1272-1280.Parisi R., Iskandar I.Y.K., Kontopantelis E., Augustin M., Griffiths C.E.M., Ashcroft D.M. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ, 2020, Vol. 369, m1590. doi: 10.1136/bmj.m1590.Petit R.G., Cano A., Ortiz A., Espina M., Prat J., Muñoz M., Severino P., Souto EB., García ML., Pujol M., Sánchez-López E. Psoriasis: From pathogenesis to pharmacological and nano-technological-based therapeutics. Int. J. Mol. Sci., 2021, Vol. 22, no. 9, 4983. doi: 10.3390/ijms22094983.Raharja A., Mahil S.K., Barker J.N. Psoriasis: a brief overview. Clin. Med., 2021, Vol. 21, no. 3, pp. 170-173.Rahman P., Elder J.T. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann. Rheum. Dis., 2005, Vol. 64, Suppl. 2, pp. ii37-ii39.Rendon A., Schäkel K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci., 2019, Vol. 20, no. 6, 1475. doi: 10.3390/ijms20061475.Tan M., Luo Y., Hu J., Hu K., Li X., Yang J., Chen J., Zhu W., Kuang Y. Elevated C-reactive protein and erythrocyte sedimentation rate correlates with depression in psoriasis: a chinese cross-sectional study. Clin. Cosmet. Investig. Dermatol., 2023, Vol. 16, pp. 397-405.Wu B., Chen Q., Cao R., Zhu L., Zhu H. Comparative effectiveness of combined biologic agents versus standard therapies in the treatment of plaque psoriasis: a retrospective analysis. Front. Med., 2024, Vol. 11, 1451069. doi: 10.3389/fmed.2024.1451069.